Type 2 diabetes comprises 90% of people with diabetes around the world. Novel oral diabetic medications without the side effects associated with earlier approaches (i.e. hypoglycemia, weight gain), are currently active areas of research in pharmaceutical industry. In these emerging approaches G protein coupled receptor 119 (GPR119) agonists have shown great promise with a glucose dependent insulin secreting mechanism. Here we describe the SAR studies leading to the discovery of a potent and orally efficacious pyridopyrimidinone based GPR119 agonist.

Pyridopyrimidinone analogs as orally efficacious GPR119 agonists

243rd National Meeting (2012)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.